Literature DB >> 3012944

Some central effects of angiotensin II. Interactions with dopaminergic transmission.

V Georgiev, L György, D Getova, V Markovska.   

Abstract

The effects of angiotensin II (AT II) administered intracerebroventricularly (i.c.v.) on some behavioural reactions were studied. AT II increased the electroshock convulsive-seizure threshold in mice. Sulpiride antagonized this effect of AT II. AT II increased the exploratory behaviour of rats in open field. This effect was potentiated by nomifensine (a dopamine uptake blocker) and was blocked by haloperidol. AT II increased apomorphine stereotypy and the effect was antagonized by saralasin and haloperidol and partly by alpha-methyl-para-tyrosine (alpha-MpT) (an inhibitor of dopamine synthesis). AT II decreased the locomotor activity of mice. At doses of 0.5 and 1 microgram per mouse AT II did not change haloperidol (5 mg/kg)- or tetrabenazine (25 mg/kg)-induced catalepsy. It is assumed that the behavioural effects of AT II are realized through angiotensin receptors and through interactions between these receptors and dopaminergic transmission in the brain structures involved in the behavioural reactions studied.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3012944

Source DB:  PubMed          Journal:  Acta Physiol Pharmacol Bulg        ISSN: 0323-9950


  3 in total

1.  Renin-Angiotensin system and sympathetic neurotransmitter release in the central nervous system of hypertension.

Authors:  Kazushi Tsuda
Journal:  Int J Hypertens       Date:  2012-11-21       Impact factor: 2.420

2.  Fear-potentiated behaviour is modulated by central amygdala angiotensin II AT1 receptors stimulation.

Authors:  Maria de los Angeles Marinzalda; Pablo A Pérez; Pascual A Gargiulo; Brenda S Casarsa; Claudia Bregonzio; Gustavo Baiardi
Journal:  Biomed Res Int       Date:  2014-06-09       Impact factor: 3.411

Review 3.  Neuropeptides as targets for the development of anticonvulsant drugs.

Authors:  Elke Clynen; Ann Swijsen; Marjolein Raijmakers; Govert Hoogland; Jean-Michel Rigo
Journal:  Mol Neurobiol       Date:  2014-04-06       Impact factor: 5.590

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.